Nektar Therapeutics (NKTR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NKTR Stock Forecast

Nektar Therapeutics stock forecast is as follows: an average price target of $16.75 (represents a 1526.21% upside from NKTR’s last price of $1.03) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

NKTR Price Target

The average price target for Nektar Therapeutics (NKTR) is $16.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $6.00. This represents a potential 1526.21% upside from NKTR's last price of $1.03.

NKTR Analyst Ratings

Buy

According to 4 Wall Street analysts, Nektar Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NKTR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Nektar Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 18, 2022	Mara Goldstein	Mizuho Securities	$6.00	$4.74	26.58%	482.52%
Mar 01, 2022	Jessica Fye	J.P. Morgan	$17.00	$10.98	54.83%	1550.49%
Nov 08, 2021	Aydin Huseynov	Ladenburg Thalmann & Co.	$20.00	$14.65	36.52%	1841.75%
May 18, 2021	Chris Shibutani	Goldman Sachs	$24.00	$18.13	32.38%	2230.10%

Row per page

Go to

The latest Nektar Therapeutics stock forecast, released on Apr 18, 2022 by Mara Goldstein from Mizuho Securities, set a price target of $6.00, which represents a 26.58% increase from the stock price at the time of the forecast ($4.74), and a 482.52% increase from NKTR last price ($1.03).

Nektar Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.03	$1.03	$1.03
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Nektar Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nektar Therapeutics's last price of $1.03. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 04, 2024	Piper Sandler	-	Overweight	Initialise
Jun 28, 2024	Rodman & Renshaw	-	Buy	Initialise
Nov 09, 2023	Cowen & Co.	-	Outperform	Upgrade
May 10, 2023	Jefferies	-	Hold	Upgrade
Mar 06, 2023	Oppenheimer	Perform	Perform	Hold

Row per page

Go to

Nektar Therapeutics's last stock rating was published by Piper Sandler on Nov 04, 2024. The company Initialise its NKTR rating from "null" to "Overweight".

Nektar Therapeutics Financial Forecast

Nektar Therapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$24.14M	$20.50M	$21.59M	$22.02M	$23.63M	$21.59M	$24.82M	$25.01M	$24.92M	$28.33M	$23.65M	$23.46M	$30.03M
Avg Forecast	$17.00M	$17.00M	$17.00M	$17.00M	$25.09M	$24.72M	$24.36M	$24.15M	$24.00M	$22.54M	$22.32M	$21.57M	$29.31M	$19.18M	$18.20M	$15.34M	$21.43M	$21.26M	$21.79M	$19.41M	$22.14M	$22.61M	$22.62M	$24.30M	$34.26M	$28.13M	$26.15M	$25.73M	$29.86M	$22.59M
High Forecast	$30.71M	$30.71M	$30.71M	$30.71M	$45.32M	$44.65M	$44.01M	$43.63M	$43.35M	$40.71M	$40.32M	$30.60M	$60.05M	$20.18M	$32.88M	$15.34M	$29.05M	$21.26M	$39.36M	$35.06M	$39.99M	$22.61M	$22.62M	$24.30M	$34.26M	$28.13M	$26.15M	$25.73M	$29.86M	$22.59M
Low Forecast	$10.36M	$10.36M	$10.36M	$10.36M	$15.29M	$15.06M	$14.85M	$14.72M	$14.63M	$13.74M	$13.60M	$12.53M	$16.82M	$18.17M	$11.09M	$15.34M	$6.39M	$21.26M	$13.28M	$11.83M	$13.49M	$22.61M	$22.62M	$24.30M	$34.26M	$28.13M	$26.15M	$25.73M	$29.86M	$22.59M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	10
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.14%	0.94%	1.11%	0.99%	1.04%	0.95%	1.02%	0.73%	0.89%	1.08%	0.92%	0.79%	1.33%

Nektar Therapeutics's average Quarter revenue forecast for Dec 23 based on 5 analysts is $21.43M, with a low forecast of $6.39M, and a high forecast of $29.05M. NKTR's average Quarter revenue forecast represents a -11.25% decrease compared to the company's last Quarter revenue of $24.14M (Sep 23).

Nektar Therapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	10
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-44.86M	$-50.60M	$-32.98M	$-37.76M	$-32.74M	$-45.70M	$-110.96M	$-134.09M	$-113.17M	$-108.53M	$-106.04M	$-105.65M	$-96.89M
Avg Forecast	$-17.00M	$-17.00M	$-17.00M	$-17.00M	$-25.09M	$-24.72M	$-24.36M	$-24.15M	$-24.00M	$-22.54M	$-22.32M	$-21.57M	$-29.31M	$-19.18M	$-18.20M	$-122.31M	$-21.43M	$-21.26M	$-21.79M	$-111.19M	$-151.14M	$-22.61M	$-22.62M	$-101.08M	$-34.26M	$-28.13M	$-26.15M	$-111.93M	$-29.86M	$-22.59M
High Forecast	$-10.36M	$-10.36M	$-10.36M	$-10.36M	$-15.29M	$-15.06M	$-14.85M	$-14.72M	$-14.63M	$-13.74M	$-13.60M	$-12.53M	$-16.82M	$-18.17M	$-11.09M	$-97.85M	$-6.39M	$-21.26M	$-13.28M	$-88.95M	$-120.91M	$-22.61M	$-22.62M	$-80.87M	$-34.26M	$-28.13M	$-26.15M	$-89.54M	$-29.86M	$-22.59M
Low Forecast	$-30.71M	$-30.71M	$-30.71M	$-30.71M	$-45.32M	$-44.65M	$-44.01M	$-43.63M	$-43.35M	$-40.71M	$-40.32M	$-30.60M	$-60.05M	$-20.18M	$-32.88M	$-146.77M	$-29.05M	$-21.26M	$-39.36M	$-133.43M	$-181.36M	$-22.61M	$-22.62M	$-121.30M	$-34.26M	$-28.13M	$-26.15M	$-134.31M	$-29.86M	$-22.59M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.11%	2.32%	0.30%	0.25%	1.45%	2.02%	1.10%	3.91%	4.02%	4.15%	0.95%	3.54%	4.29%

undefined analysts predict NKTR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nektar Therapeutics's previous annual EBITDA (undefined) of $NaN.

Nektar Therapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	10
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-45.84M	$-51.12M	$-137.02M	$-59.69M	$-59.05M	$-159.07M	$-90.39M	$-145.65M	$-129.71M	$-125.52M	$-122.97M	$-117.20M	$-108.59M
Avg Forecast	$-44.99M	$-45.43M	$-45.89M	$-46.75M	$-48.43M	$-48.66M	$-47.38M	$-45.73M	$-40.98M	$-40.87M	$-39.16M	$-41.39M	$-34.25M	$-41.64M	$-38.71M	$-139.94M	$-44.03M	$-41.50M	$-58.90M	$-127.21M	$-164.17M	$-93.76M	$-202.56M	$-115.65M	$-167.76M	$-166.65M	$-152.62M	$-129.80M	$-142.06M	$-157.74M
High Forecast	$-22.15M	$-22.36M	$-22.59M	$-23.01M	$-23.84M	$-23.95M	$-23.32M	$-22.51M	$-20.17M	$-20.12M	$-19.28M	$-31.53M	$-21.41M	$-20.50M	$-19.06M	$-111.95M	$-35.23M	$-20.43M	$-28.99M	$-101.77M	$-131.33M	$-93.76M	$-202.56M	$-92.52M	$-167.76M	$-166.65M	$-152.62M	$-103.84M	$-142.06M	$-157.74M
Low Forecast	$-92.15M	$-93.05M	$-93.99M	$-95.75M	$-99.20M	$-99.67M	$-97.06M	$-93.67M	$-83.94M	$-83.72M	$-80.21M	$-49.27M	$-51.38M	$-85.30M	$-79.29M	$-167.92M	$-50.64M	$-85.00M	$-120.64M	$-152.66M	$-197.00M	$-93.76M	$-202.56M	$-138.78M	$-167.76M	$-166.65M	$-152.62M	$-155.76M	$-142.06M	$-157.74M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.10%	0.87%	1.08%	0.36%	0.63%	0.79%	0.78%	0.87%	0.78%	0.82%	0.95%	0.83%	0.69%

Nektar Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NKTR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Nektar Therapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	10
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$21.15M	$17.87M	$21.08M	$21.94M	$22.53M	$20.52M	$27.34M	$32.14M	$29.47M	$29.55M	$31.68M	$27.14M	$26.98M
Avg Forecast	$15.77M	$15.77M	$15.77M	$15.77M	$23.27M	$22.93M	$22.60M	$22.40M	$22.26M	$20.90M	$20.71M	$20.00M	$27.18M	$17.79M	$16.89M	$14.23M	$19.88M	$19.72M	$20.21M	$18.00M	$20.53M	$20.97M	$20.98M	$22.54M	$31.78M	$26.10M	$24.26M	$23.86M	$27.69M	$20.95M
High Forecast	$28.48M	$28.48M	$28.48M	$28.48M	$42.04M	$41.41M	$40.82M	$40.47M	$40.21M	$37.76M	$37.40M	$28.38M	$55.70M	$18.72M	$30.50M	$14.23M	$26.95M	$19.72M	$36.51M	$32.52M	$37.09M	$20.97M	$20.98M	$22.54M	$31.78M	$26.10M	$24.26M	$23.86M	$27.69M	$20.95M
Low Forecast	$9.61M	$9.61M	$9.61M	$9.61M	$14.18M	$13.97M	$13.77M	$13.65M	$13.57M	$12.74M	$12.62M	$11.62M	$15.60M	$16.86M	$10.29M	$14.23M	$5.93M	$19.72M	$12.32M	$10.97M	$12.51M	$20.97M	$20.98M	$22.54M	$31.78M	$26.10M	$24.26M	$23.86M	$27.69M	$20.95M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07%	0.88%	1.17%	1.07%	1.07%	0.98%	1.21%	1.01%	1.13%	1.22%	1.33%	0.98%	1.29%

Nektar Therapeutics's average Quarter SG&A projection for Dec 23 is $19.88M, based on 5 Wall Street analysts, with a range of $5.93M to $26.95M. The forecast indicates a -6.01% fall compared to NKTR last annual SG&A of $21.15M (Sep 23).

Nektar Therapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	10	10
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.24	$-0.27	$-0.73	$-0.32	$-0.31	$-0.85	$-0.49	$-0.79	$-0.70	$-0.69	$-0.68	$-0.65	$-0.61
Avg Forecast	$-0.21	$-0.22	$-0.22	$-0.22	$-0.23	$-0.23	$-0.23	$-0.22	$-0.20	$-0.20	$-0.19	$-0.20	$-0.16	$-0.20	$-0.18	$-0.19	$-0.21	$-0.20	$-0.28	$-0.25	$-0.45	$-0.45	$-0.97	$-0.63	$-0.80	$-0.80	$-0.73	$-0.73	$-0.68	$-0.76
High Forecast	$-0.11	$-0.11	$-0.11	$-0.11	$-0.11	$-0.11	$-0.11	$-0.11	$-0.10	$-0.10	$-0.09	$-0.15	$-0.10	$-0.10	$-0.09	$-0.09	$-0.17	$-0.10	$-0.14	$-0.12	$-0.22	$-0.45	$-0.97	$-0.63	$-0.80	$-0.80	$-0.73	$-0.73	$-0.68	$-0.76
Low Forecast	$-0.44	$-0.44	$-0.45	$-0.46	$-0.47	$-0.48	$-0.46	$-0.45	$-0.40	$-0.40	$-0.38	$-0.24	$-0.25	$-0.41	$-0.38	$-0.39	$-0.24	$-0.41	$-0.58	$-0.51	$-0.93	$-0.45	$-0.97	$-0.63	$-0.80	$-0.80	$-0.73	$-0.73	$-0.68	$-0.76
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.21%	0.96%	2.94%	0.71%	0.69%	0.88%	0.78%	0.98%	0.88%	0.94%	0.93%	0.96%	0.81%

According to undefined Wall Street analysts, Nektar Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NKTR previous annual EPS of $NaN (undefined).

Nektar Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
NKTR	Nektar Therapeutics	$1.03	$16.75	1526.21%	Buy
SPRO	Spero Therapeutics	$1.16	$10.00	762.07%	Buy
CTMX	CytomX Therapeutics	$0.89	$5.73	543.82%	Buy
TIL	Instil Bio	$26.20	$78.25	198.66%	Hold
NUVB	Nuvation Bio	$2.59	$6.75	160.62%	Buy
ASMB	Assembly Biosciences	$15.34	$35.50	131.42%	Buy
NXTC	NextCure	$1.31	$3.00	129.01%	Buy
ACHL	Achilles Therapeutics	$1.05	$2.00	90.48%	Buy

NKTR Forecast FAQ

Is Nektar Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Nektar Therapeutics (NKTR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of NKTR's total ratings.

What is NKTR's price target?

Nektar Therapeutics (NKTR) average price target is $16.75 with a range of $6 to $24, implying a 1526.21% from its last price of $1.03. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Nektar Therapeutics stock go up soon?

According to Wall Street analysts' prediction for NKTR stock, the company can go up by 1526.21% (from the last price of $1.03 to the average price target of $16.75), up by 2230.10% based on the highest stock price target, and up by 482.52% based on the lowest stock price target.

Can Nektar Therapeutics stock reach $2?

NKTR's average twelve months analyst stock price target of $16.75 supports the claim that Nektar Therapeutics can reach $2 in the near future.

What are Nektar Therapeutics's analysts' financial forecasts?

Nektar Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $98.32M (high $177.61M, low $59.92M), average EBITDA is $-98.323M (high $-59.921M, low $-178M), average net income is $-190M (high $-93.631M, low $-390M), average SG&A $91.2M (high $164.74M, low $55.58M), and average EPS is $-0.909 (high $-0.447, low $-1.862). NKTR's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $68M (high $122.83M, low $41.44M), average EBITDA is $-68M (high $-41.441M, low $-123M), average net income is $-183M (high $-90.109M, low $-375M), average SG&A $63.07M (high $113.93M, low $38.44M), and average EPS is $-0.875 (high $-0.431, low $-1.792).

Did the NKTR's actual financial results beat the analysts' financial forecasts?

Based on Nektar Therapeutics's last annual report (Dec 2023), the company's revenue was $90.12M, beating the average analysts forecast of $83.89M by 7.43%. Apple's EBITDA was $-264M, beating the average prediction of $-176M by 50.10%. The company's net income was $-276M, beating the average estimation of $-272M by 1.62%. Apple's SG&A was $77.42M, missing the average forecast of $77.81M by -0.51%. Lastly, the company's EPS was $-1.45, beating the average prediction of $-0.938 by 54.54%. In terms of the last quarterly report (Sep 2023), Nektar Therapeutics's revenue was $24.14M, beating the average analysts' forecast of $21.26M by 13.54%. The company's EBITDA was $-44.864M, beating the average prediction of $-21.264M by 110.98%. Nektar Therapeutics's net income was $-45.837M, beating the average estimation of $-41.496M by 10.46%. The company's SG&A was $21.15M, beating the average forecast of $19.72M by 7.22%. Lastly, the company's EPS was $-0.24, beating the average prediction of $-0.198 by 21.02%